表纸
市场调查报告书

Opioids(类鸦片物质)诱发性便秘 - 开发平台分析

Constipation - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品编码 257786
出版日期 内容资讯 英文 111 Pages
订单完成后即时交付
价格
Back to Top
Opioids(类鸦片物质)诱发性便秘 - 开发平台分析 Constipation - Pipeline Review, H2 2019
出版日期: 2019年09月23日内容资讯: 英文 111 Pages
简介

Opioids(类鸦片物质)是有效的止痛药,但偶而会有造成便秘的副作用。这些药物皆会以各种形式影响消化器官。譬如由于Opioids(类鸦片物质)造成粪便在消化器官内移动速度减缓。在小肠中造成非推动性收缩,抑制了蠕动这个纵向推动力。结果造成食物在消化道中无法移动。Opioids(类鸦片物质)所造成的部分胃麻痺(胃不全麻痺)也会让食物长期停留在消化器官中。不仅如此,Opioids(类鸦片物质)还会减少消化液的分泌,并抑制便意的产生。Opioids(类鸦片物质)诱发性便秘的症状有感觉恶心、想吐、疲劳、无力、食欲不振等及心情低落。

本报告提供Opioids(类鸦片物质)诱发性便秘的治疗药开发平台现况及最新更新的各开发阶段比较分析,提供您企业和研究机关开发中的治疗药,治疗药评估,后期阶段及中止的计划等相关资讯,以及最新的新闻和发表等资料。

简介

  • 调查范围

Opioids(类鸦片物质)诱发性便秘 概要

治疗药的开发

  • 开发中产品;概要
  • 开发中产品;比较分析

企业开发中的治疗药

开发中产品概况

  • 后期阶段的产品
  • 临床阶段的产品

企业开发中的产品

治疗药的开发企业

  • AstraZeneca PLC
  • Cosmo Pharmaceuticals S.p.A
  • Cubist Pharmaceuticals, Inc.
  • Develco Pharma Schweiz AG
  • Ironwood Pharmaceuticals, Inc.
  • S.L.A. Pharma AG
  • Salix Pharmaceuticals Ltd.
  • 鹽野义制药
  • Sucampo Pharmaceuticals, Inc.
  • Synergy Pharmaceuticals, Inc.

治疗药的评估

  • 单剂产品
  • 标的别
  • 各作用机制
  • 各给药途径
  • 各分子类型

药物简介

  • axelopran
  • bevenopran
  • linaclotide
  • lubiprostone
  • methylnaltrexone bromide
  • naldemedine
  • naloxegol oxalate
  • naloxone hydrochloride
  • naloxone hydrochloride PR
  • naloxone hydrochloride SR
  • SP-333

最近的开发平台趋势

暂停中的计划

开发中止的产品

产品开发的里程碑

  • 主要消息和新闻稿

附录

图表

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC11400IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Constipation - Pipeline Review, H2 2019, provides an overview of the Constipation (Gastrointestinal) pipeline landscape.

Constipation refers to the infrequent or difficult passing of stool. Constipation occurs when bowel movements become difficult or less frequent. Symptoms of constipation include swollen abdomen or abdominal pain, pain and vomiting. The predisposing factors include eating disorders, irritable bowel syndrome, and hypothyroidism, overuse of laxatives (stool softeners) which, over time, weaken the bowel muscles, stress, inadequate water intake and inadequate fiber in the diet. Treatment includes use of laxatives and proper lifestyle.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Constipation - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Constipation (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Constipation (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Constipation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 2, 7, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Constipation (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Constipation (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Constipation (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Constipation (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Constipation (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Constipation (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Constipation (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Constipation (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
    • Constipation - Overview
    • Constipation - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Constipation - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Constipation - Companies Involved in Therapeutics Development
    • Allergan Plc
    • Ardelyx Inc
    • Bausch Health Companies Inc
    • Braintree Laboratories Inc
    • Dong-A ST Co Ltd
    • Enterin Inc
    • Inhibikase Therapeutics Inc
    • Ironwood Pharmaceuticals Inc
    • Kissei Pharmaceutical Co Ltd
    • Mallinckrodt Plc
    • NGM Biopharmaceuticals Inc
    • RaQualia Pharma Inc
    • Renexxion LLC
    • Sanwa Kagaku Kenkyusho Co Ltd
    • Synthetic Biologics Inc
    • Yuhan Corp
    • Zensun (Shanghai) Sci & Tech Co Ltd
  • Constipation - Drug Profiles
    • 5-BIOP - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BLI-400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BLI-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DA-6886 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ENT-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IkT-148009 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lactulose 1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • linaclotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lovastatin MR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lubiprostone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mizagliflozin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naronapride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NGM-282 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plecanatide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RQ-00000010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tenapanor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YH-12852 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZS-06 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Constipation - Dormant Projects
  • Constipation - Discontinued Products
  • Constipation - Product Development Milestones
    • Featured News & Press Releases
      • Jul 22, 2019: Ironwood Pharmaceuticals Allergan provides update on its ANDA Lawsuit
      • Jun 26, 2019: Knight announces filing of New Drug Submission for Ibsrela in Canada
      • Jun 20, 2019: Ironwood and Allergan's LINZESS trial meets primary endpoint
      • May 14, 2019: Salix Pharmaceuticals presents data on TRULANCE at Digestive Disease Week
      • May 09, 2019: Ironwood Pharmaceuticals to highlight linaclotide data at Digestive Disease Week 2019
      • Jan 18, 2019: Linzess (linaclotide) approved in China for the treatment of irritable bowel syndrome with constipation
      • Jan 04, 2019: Ironwood and Allergan settle Linzess patent litigation with Mylan
      • Jan 03, 2019: Synthetic Biologics announces first two patients enrolled in phase 2b investigator-sponsored
      • Dec 17, 2018: Cipher Pharmaceuticals announces PLECANATIDE accepted for review by Health Canada
      • Nov 13, 2018: Ardelyx announces FDA acceptance of the filing of its New Drug Application for Tenapanor for the treatment of patients with IBS-C
      • Oct 25, 2018: Synergy Pharmaceuticals provides business update
      • Oct 08, 2018: Synergy pharmaceuticals presents new analyses supporting the use of TRULANCE (Plecanatide) in two patient populations at the American College of Gastroenterology (ACG) Annual Scientific Meeting
      • Oct 08, 2018: Ironwood Pharmaceuticals presenting Linaclotide Data at the American College of Gastroenterology 2018 Annual Scientific Meeting
      • Oct 08, 2018: Ardelyx showcases new data from T3MPO-3 long-term safety trial of Tenapanor for IBS-C in presidential poster at ACG 2018 Annual Meeting
      • Oct 01, 2018: Synergy Pharmaceuticals to present new analyses of TRULANCE (Plecanatide) at the American College of Gastroenterology (ACG) Annual Scientific Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Constipation, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Constipation - Pipeline by Allergan Plc, H2 2019
  • Constipation - Pipeline by Ardelyx Inc, H2 2019
  • Constipation - Pipeline by Bausch Health Companies Inc, H2 2019
  • Constipation - Pipeline by Braintree Laboratories Inc, H2 2019
  • Constipation - Pipeline by Dong-A ST Co Ltd, H2 2019
  • Constipation - Pipeline by Enterin Inc, H2 2019
  • Constipation - Pipeline by Inhibikase Therapeutics Inc, H2 2019
  • Constipation - Pipeline by Ironwood Pharmaceuticals Inc, H2 2019
  • Constipation - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2019
  • Constipation - Pipeline by Mallinckrodt Plc, H2 2019
  • Constipation - Pipeline by NGM Biopharmaceuticals Inc, H2 2019
  • Constipation - Pipeline by RaQualia Pharma Inc, H2 2019
  • Constipation - Pipeline by Renexxion LLC, H2 2019
  • Constipation - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2019
  • Constipation - Pipeline by Synthetic Biologics Inc, H2 2019
  • Constipation - Pipeline by Yuhan Corp, H2 2019
  • Constipation - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2019
  • Constipation - Dormant Projects, H2 2019
  • Constipation - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Constipation - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Constipation, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top